Biocon, Ltd.’s biosimilars business appears to have regained some momentum in the first quarter of fiscal 2021, after a tough previous quarter impacted by COVID-19-related challenges. The Indian firm is confident of a continued uptick in the US, where it sees headroom for greater affordability for biosimilars.
Revenues in the biosimilars segment rose by 19% to INR6.92bn ($92.6m) in the three-month period ended 30 June, led by...